Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $427000.0.

  • Pulse Biosciences' Change in Accured Expenses fell 3348.91% to $427000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 6915.54%. This contributed to the annual value of $3.2 million for FY2024, which is 16349.47% up from last year.
  • Per Pulse Biosciences' latest filing, its Change in Accured Expenses stood at $427000.0 for Q3 2025, which was down 3348.91% from $793000.0 recorded in Q2 2025.
  • In the past 5 years, Pulse Biosciences' Change in Accured Expenses ranged from a high of $3.2 million in Q4 2024 and a low of -$3.0 million during Q1 2025
  • Its 5-year average for Change in Accured Expenses is -$6473.7, with a median of $215000.0 in 2022.
  • In the last 5 years, Pulse Biosciences' Change in Accured Expenses tumbled by 41728.4% in 2023 and then surged by 45447.47% in 2024.
  • Quarter analysis of 5 years shows Pulse Biosciences' Change in Accured Expenses stood at -$582000.0 in 2021, then tumbled by 138.32% to -$1.4 million in 2022, then surged by 158.4% to $810000.0 in 2023, then skyrocketed by 295.68% to $3.2 million in 2024, then crashed by 86.68% to $427000.0 in 2025.
  • Its last three reported values are $427000.0 in Q3 2025, $793000.0 for Q2 2025, and -$3.0 million during Q1 2025.